[EN] SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION<br/>[FR] PETITES MOLÉCULES DIRIGÉES CONTRE LE CÉRÉBLON POUR AMÉLIORER LA FONCTION DES LYMPHOCYTES T EFFECTEURS
申请人:H LEE MOFFITT CANCER CENTER & RES INST INC
公开号:WO2017161119A1
公开(公告)日:2017-09-21
Disclosed are small molecules against cereblon to enhance effector T cell function. Methodos of making thes molecules and methods of using them to treat various disease states are also disclosed.
Small molecules against cereblon to enhance effector t cell function
申请人:H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
公开号:US11395820B2
公开(公告)日:2022-07-26
Disclosed are small molecules against cereblon to enhance effector T cell function. Methods of making these molecules and methods of using them to treat various disease states are also disclosed.
所公开的是抗脑龙的小分子,可增强效应 T 细胞的功能。还公开了制造这些分子的方法以及用它们治疗各种疾病的方法。
One-pot synthesis of N-alkyl purine and pyrimidine derivatives from alcohols using TsIm: a rapid entry into carboacyclic nucleoside synthesis
作者:Mohammad Navid Soltani Rad、Ali Khalafi-Nezhad、Somayeh Behrouz、Mohammad Ali Faghihi、Abdolkarim Zare、Abolfath Parhami
DOI:10.1016/j.tet.2007.11.101
日期:2008.2
A convenient and efficient one-pot N-alkylation of nucleobases from alcohols using N-(p-toluenesulfonyl)imidazole (TsIm) is described. In this method, treatment of alcohols with a mixture of purine or pyrimidine nucleobase, TsIm, K2CO3, and triethylamine in refluxing DMF regioselectively furnishes the corresponding N-alkyl nucleobases in good yields. This methodology is highly efficient for various structurally diverse primary alcohols. (C) 2007 Elsevier Ltd. All rights reserved.
SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION
申请人:H. Lee Moffitt Cancer Center And
Research Institute, Inc.
公开号:EP3429996A1
公开(公告)日:2019-01-23
OXYTOCIN ANTAGONIST DOSING REGIMENS FOR PROMOTING EMBRYO IMPLANTATION AND PREVENTING MISCARRIAGE
申请人:ObsEva S.A.
公开号:US20190247361A1
公开(公告)日:2019-08-15
The invention provides compositions and methods for the use of oxytocin antagonists, such as substituted pyrrolidin-3-one oxime derivatives, among other compounds, in the treatment of subjects undergoing embryo transfer therapy. The compositions and methods of the invention can be used to dose subjects with oxytocin antagonists, including (3Z,55)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, among others, so as to improve endometrial receptivity and reduce the likelihood of embryo implantation failure and miscarriage following, for example, in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) embryo transfer procedures.